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Cytochrome P450 1B1 (CYP1B1) is involved in the activation of
many carcinogens and in the metabolism of steroid hormones. We
compared allele, genotype and haplotype frequencies of six single-
nucleotide polymorphisms (SNPs) within CYP1B1 among
non-Hispanic Caucasians (496 cases and 498 controls) and His-
panic Caucasians (153 cases and 240 controls). In the Hispanic
Caucasians, the GG genotype for rs1056836 decreased the risk for
prostate cancer (PCa) when compared with the CC genotype
[odds ratio (OR) 5 0.31, P 5 0.04, 95% conﬁdence interval
(CI) 5 0.10–0.96]. Among non-Hispanic Caucasian men with more
aggressive PCa, the prevalence of several SNPs (rs2567206,
rs2551188, rs2617266, rs10012 and rs1056836) was signiﬁcantly
associated with the disease status. A common C-G-C-C-G-A hap-
lotype for rs2567206-rs2551188-rs2617266-rs10012-rs1056836-
rs1800440 showed an inverse association with PCa risk in
Hispanic Caucasians (OR 5 0.19, P 5 0.04, 95% CI 5 0.04–
0.95) and with aggressive disease status (i.e. Gleason score ‡7)
in non-Hispanic Caucasian cases (OR 5 0.64, P 5 0.008, 95%
CI 5 0.47–0.89). In the non-Hispanic Caucasian cases, a second
major haplotype T-A-T-G-C-A was positively associated with the
high-grade disease status (OR 5 1.77, P 5 0.002, 95% CI 5
1.24–2.53). Our ﬁndings suggest that genetic polymorphisms in
CYP1B1 may modify the risk for PCa and support the role of
CYP1B1 as a candidate gene for PCa.
Introduction
The diagnosis of prostate cancer (PCa; MIM 176807) is common—in
the USA approximately one in six men is diagnosed with PCa in
his lifetime (1). PCa is the most common non-skin cancer and the
second leading cause of cancer death in men in USA. It is estimated
that there would be 218 890 new cases of PCa and 27 050 deaths
resulting from PCa in 2007 in USA (1). The underlying etiology of
PCa remains poorly understood, with both genetic predisposition and
environmental factors likely to play a role. From a large twin study,
the proportion of PCa risk accounted for by inheritable factors
was estimated to be 42% [95% conﬁdence interval (CI) 5 29–50%]
(2). Heritable risk factors can involve highly penetrant susceptibility
genes with low frequencies and/or low penetrant genes with
higher frequencies in the population. A segregation study in 263
PCa families found that the disease is more probable due to the
contributions of two to four PCa susceptibility genes than one gene
(3) which corroborates earlier predictions that the majority of PCa
cases most likely involve more common, low- to moderate-penetrant
alleles in genes that are components of pathways that inﬂuence pros-
tate function (4–6).
The cytochromes P450 (P450) are a very large gene family of
constitutive and inducible enzymes with a major role in the oxidative
activation and/or deactivation of a wide range of xenobiotics, includ-
ing many potential carcinogens and several anticancer drugs (7).
Cytochrome P450 1B1 (CYP1B1) is a member of the CYP1 gene
family and one of the major enzymes involved in the hydroxylation
of estrogens, a reaction of key relevance in hormonal carcinogenesis
(8). Particularly, CYP1B1 catalyzes the hydroxylation of 17b-estra-
diol (E2) at the C4 position (9,10) and testosterone at the C6b and C12a
positions (11).
The human CYP1B1 gene (CYP1B1, MIM 601771) has been map-
ped to chromosomal region 2p21–p22 (12) and is composed of three
exons and two introns spanning  12 kb of DNA (13). The mRNA is
5.2 kb and the open reading frame begins at the 5# end of the second
exon. The predicted protein sequence is 543 amino acids. Although
CYP1B1 is expressed in a wide variety of tissues, expression is par-
ticularly high in the prostate, breast and ovary (14–16). Furthermore,
no CYP1B1 protein expression was detected in normal prostate tissue
in contrast to the overexpression of CYP1B1 protein in prostate
carcinoma (17).
More evidence for a potential role of CYP1B1 in carcinogenesis
comes from several observations; CYP1B1 interacts with a number of
structurally diverse clinically useful anticancer agents in a substrate-
dependent manner (18). The importance of CYP1B1 in chemical car-
cinogens is well illustrated in animal models in which metabolites of
CYP1B1 have been shown to induce PCa (19,20). Furthermore,
CYP1B1-null mice, created by targeted gene disruption in embryonic
stem cells, were protected from 7,12-dimethylbenz(a)anthracene-
induced malignant lymphomas (21). McGrath et al. reported on the
correlation of a polymorphism that increases the degradation efﬁ-
ciency of CYP1B1 with decreased cancer risk, suggesting that an
increased rate of CYP1B1 protein degradation mediates a protective
effect against tumorigenesis (22,23).
Several polymorphisms in the CYP1B1 gene have been described
(see http://www.imm.ki.se/CYPalleles/cyp1b1.htm), of which four
results in amino acid substitutions, including the common single-
nucleotide polymorphisms (SNPs) rs10012, rs1056827, rs1056836
and rs1800440. Functional studies suggest that these non-synonymous
SNPs may alter enzymatic activity and catalytic speciﬁcity of
CYP1B1 (24–26). Several studies have evaluated the relationship be-
tween CYP1B1 polymorphisms and the risk of cancers, including
PCa. An association between rs1056836 and the risk of PCa was
found among Caucasians and Japanese, respectively (27,28). Others
found that carrying the CYP1B1 rs1056827 T allele was positively
associated with PCa in Japanese and in Caucasian cancer cases
(29,30). Furthermore, a common haplotype C-G-C-C-G for the
rs2567206-rs2551188-rs2617266-rs10012-rs1056827 combination was
associated with an increased risk for PCa (31) and the CYP1B1
rs1056827(T)-rs1056836(C) haplotype was positively associated with
PCa among men with high aggressive disease (30).
To date, no association study of CYP1B1 variants has been reported
in Hispanic Caucasian PCa cases. We therefore performed a case–control
study among non-Hispanic Caucasians and Hispanic Caucasians and
Abbreviations: CI, conﬁdence interval; CYP1B1, cytochrome P450 1B1;
MAF, minimum allele frequency; OR, odds ratio; PCa, prostate cancer; SNP,
single-nucleotide polymorphism.
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Materials and methods
Study participants
Participants used in this study were part of the San Antonio Center for
Biomarkers of Risk of Prostate Cancer cohort. San Antonio Center for Bio-
markers of Risk of Prostate Cancer is funded by the National Cancer Institute
and has been prospectively enrolling healthy male volunteers between 2001
and 2007. On each annual visit, a digital rectal examination was performed and
prostate-speciﬁc antigen level was determined. From this cohort, 183 incident
cases (124 non-Hispanic Caucasians and 59 Hispanic Caucasians) were avail-
able. We also included 520 cases with a known history of PCa which are
enrolled within the same time period in a parallel study of prevalent PCa from
the same metropolitan population and recruited using the same means. The
prevalent cases had a median time period of 3 years (range 0–25 years) be-
tween disease diagnosis and enrollment into the study. Cases had biopsy-con-
ﬁrmed PCa and controls consisted of male volunteers of at least 45 years old
who had normal digital rectal examinations and prostate-speciﬁc antigen levels
,2.5 ng/ml on at least two and up to six study visits. Race/ethnicity was self-
reported on a questionnaire ﬁlled out at a clinic site at the time of recruiting.
We used the Hazuda model to deﬁne the racial/ethnic groups (32). All partic-
ipants have established USA residency and are believed to be long-term res-
idents. Clinical characteristics of the study group are shown in Table I. A total
of 994 non-Hispanic Caucasians (496 cases and 498 controls) and 393 His-
panic Caucasians (153 cases and 240 controls) were selected for this study.
This studyreceived InstitutionalReviewBoard approval from the University of
Texas Health Science Center at San Antonio and informed consent was ob-
tained from all subjects. For the purposes of determining whether variants
within CYP1B1 are associated with the disease aggressiveness, we subdivided
the cases of each ethnic group in two subgroups: men with a low grade of
aggressiveness (Gleason score ,7) and men with a high grade of aggressive-
ness (Gleason score  7). Gleason score data were available for 382 non-
Hispanic Caucasians (225 with low grade and 157 with high grade) and 132
Hispanic Caucasians (69 with low grade and 63 with high grade).
DNA isolation and genotyping
DNAwas isolated from participants’ whole blood cells using a QIAamp DNA
Blood Maxi Kit (Qiagen, Valencia, CA). Seven SNPs, rs2567206, rs2551188,
rs2617266, rs10012,rs1056827, rs1056836 andrs1800440wereselectedwithin
CYP1B1 based on the following criteria: (i) for replication purposes, we pref-
erentially choose SNPs that have been reported and for which signiﬁcant data
were found; (ii) we used the most common non-synonymous SNPs with a min-
imum allele frequency (MAF) . 0.1 and (iii) we included intronic SNPs with
a MAF . 0.2 to obtain as optimal coverage of the gene as possible. Intronic
polymorphisms, either individually or in combination, may affect gene expres-
sion or mRNA splicing efﬁciency (33–35). Table II shows the primer and probe
sequences for the seven SNPs analyzed in this study. SNPs rs2567206,
rs2551188, rs2617266, rs10012 and rs1056836 were provided by Applied Bio-
systems (ABI, Foster City, CA) using their assay-by-design method and ana-
lyzed using their standard TaqMan allelic discrimination reaction conditions.
Primers and probes for the rs1800440 variant were designed using Primer
Express (ABI) and this SNP was genotyped using the TaqMan allelic discrim-
ination assays consisting of 10 ng/ll of genomic DNA, 900 nM of each primer,
200 nM of each probe and 1  TaqMan Universal Master Mix. Cycling con-
ditions were95Cfor10min followed by40cycles ofdenaturing at95Cf o r1 5
s and annealing/extending at 60C for 1 min. Genotypes were determined using
an ABI 7900 Sequence Detection System using the SDS 2.1 software (ABI,
Foster City, CA). For the rs1056827 variant, the target sequences were ampli-
ﬁed by polymerase chain reaction in 20 ll reaction mix containing 35 ng of
genomic DNA, 750 nM of each primer, 200 nM of each probe, 200 lMd e -
oxyribonucleotide triphosphates 1  Qiagen buffer containing MgCl2,1   Q-
solutionand1UQiagenTaq polymerase.Afterinitialdenaturationat95Cfor2
min, reactions were carried out for 35 cycles at 94C for 30 s, 51C for 30 s and
72C for 30 s. The polymerase chain reaction products of 635 bp were digested
without further puriﬁcation with 2 units of NaeI restriction enzyme (New
England Biolabs3, Ipswich, MA) at 37C for 2 h. After digestion, samples were
run on a 3% agarose gel and the digested products were classiﬁed into
Table I. Clinical data of the study group
Subgroup No. of cases
(n 5 706)
No. of controls
(n 5 1334)
Ethnic background, n (%)
Non-Hispanic Caucasian 536 (76.0) 833 (62.4)
Hispanic Caucasian 170 (24.0) 501 (37.6)
Age, n (%)
 50 18 (2.6) 163 (12.2)
51–60 146 (21.0) 503 (37.7)
61–70 313 (44.6) 443 (33.2)
.70 223 (31.8) 225 (16.9)
Mean 66 (SD 8.2) 60.8 (SD 9.1)
Prostate-speciﬁc antigen (ng/ml)
 4.0 147 1337
4.1–10.0 30 0
10.1–20.0 1 0
.20.0 5 0
Mean 4.67 (SD 19.3) 0.87 (SD 0.46)
Family history of PCa, n (%)
Negative 504 (71.6) 1084 (81.2)
Positive 200 (28.4) 250 (18.8)
Gleason, n (%) n 5 514
Non-Hispanic Caucasian
,7 225 (59)
7 103 (27)
.7 54 (14)
Hispanic Caucasian
,7 69 (52)
7 39 (30)
.7 24 (18)
SD, standard deviation.
Table II. Position, nucleotide variation, primer and probe sequences of seven SNPs within CYP1B1
SNP dbSNP ID Location Chromosome
position
AA
change
Alleles F and R primer sequences Probe sequences
 1001C/T rs2567206 Promoter 38215182 C/T F: GGTAACCGCGCTTCATCAC CTCCAATCA/GAGGCCG
R: TGTACCGAGCGTGGTTCTG
 263G/A rs2551188 Intron 1 38214445 A/G F: CGCAAGGCGCGTAACG TCCCCAG/AATTGCA
R: CGCCACCGCCTCGAT
 13C/T rs2617266 Intron 1 38214195 C/T F: CTGCACCCCTGAGTGTCA CCTTCTCCTC/TTCTGTCC
R: GGCTGGTGCCCATGCT
142C/G (R48G) rs10012 Exon 2 38214041 Arg/Gly C/G F: GCTGCTGAGGCAACGGA CAGCTCC/GGGTCCGC
R: CAGTGGCCACGCAAACG
355G/T (A119S) rs1056827 Exon 2 38213828 Ala/Ser G/T F: AGACCACGCTCCTGCTACTC
R: GAACTCTTCGTTGTGGCTGA
4326C/G(L432V) rs1056836 Exon 3 38209854 Leu/Val C/G F: TGTCAACCAGTGGTCTGTGAATC ATGACCCAC/GTGAAGTG
R: TGGATCAAAGTTCTCCGGGTTA
4390A/G(N453S) rs1800440 Exon 3 38209790 Asn/Ser A/G F: ACTTTGATCCAGCTCGATTCTTG CTCATCAG/ACAAGGAC
R: CGCCTTTTGCCCACTGAA
F, forward; R, reverse.
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1752homozygotes for the Ala/Ala alleles (340 and 295 bp fragments), homozygotes
for the Ser/Ser alleles (635 bp fragment) and heterozygotes (635, 340 and 295
bp fragments). To ensure quality control of the genotyping results,  5% of the
samples were randomly selected and regenotyped for each SNP.
Statistics
The allele frequency for each SNP was determined for the two ethnic groups
individually and the frequencies among the case–control groups or cases with
and without family history were compared using the chi-square test. Associ-
ation analyses were performed using R statistical software version 2.5.1 and
were stratiﬁed by ethnicity. The odds ratio (OR) and its 95% CI was estimated
by unconditional logistic regression as a measure of the associations between
genotypesandPCariskandalso tocompareassociationsofGleasongrade(low
grade ,7 versus high grade  7) among PCa cases. The homozygous carriers
of the common allele as determined in the whole sample group represented the
reference group in the SNP analysis. Study age among controls was the age at
last follow-up, and age among cases was the age at PCa diagnosis. Our control
group was younger than our PCa cases with a mean age (standard deviation) of
60.8 (9.1) years for the control samples and a mean age (standard deviation) of
66 (8.2) for the cases (P , 0.0001). Because of this difference and the fact that
PCa risk increases with age, all the ORs were adjusted for age. Logistic
regression was used to calculate the ORs of the haplotypes using the method
implemented in the haplo.ccs package (36). Only major haplotypes, with an
estimated frequency of .5%, are considered in this report. The model was ﬁt
for each major haplotype so that the OR of each major haplotype was
computed relative to a reference group consisting of all other haplotypes in-
cluding rare haplotypes. Three genetic models (additive, dominant and reces-
sive) were tested, with age as a covariate. All statistical tests were two-sided
and signiﬁcance was set at P , 0.05. To measure linkage disequilibrium and
deﬁne the block structure between the markers for each race/ethnicity, we used
Haploview version 4 beta 15 [(37); http://www.broad.mit.edu/mpg/haploview/].
Results
Allele frequencies
To decrease confounding because of population admixture, we ana-
lyzed the two race/ethnic groups separately. All allelic distributions in
the Hispanic Caucasian samples were in Hardy–Weinberg equilib-
rium. In the non-Hispanic Caucasians marker rs1056827 showed a
deviation from Hardy–Weinberg equilibrium (P 5 0.001). Upon re-
genotyping this marker in our samples, we found a high error rate in
both ethnic groups (whereas for the other SNPs the rate was ,1.5%)
and therefore this marker was left out in further analyses (data not
shown). No signiﬁcant differences were found in the allelic frequen-
cies between the cases and controls of each ethnic group (Table III).
We also looked at the allelic distributions between cases with and
without a family history but did not ﬁnd signiﬁcant differences be-
tween the two groups (data not shown).
Association of SNPs with PCa risk or disease aggressiveness
When each of the SNPs was analyzed separately, age-adjusted logistic
regression analysis demonstrated that Hispanic Caucasian carriers of
the GG genotype when compared with the CC genotype showed
a marginally signiﬁcant decreased risk for PCa (OR 5 0.31,
P 5 0.04, 95% CI 5 0.10–0.96; Table IV). No signiﬁcant relationships
between any of the SNPs and PCa were observed in non-Hispanic
Caucasians (Table IV). However, among non-Hispanic Caucasian
men with more aggressive PCa (Gleason grade  7), variants
rs2567206, rs2551188, rs2617266, rs10012 and rs1056836 were di-
rectly correlated with the disease aggressiveness (Table V). Positive
associations with aggressive disease were found for four SNPs with
ORs ranging from 1.64 (95% CI 5 1.05–2.57; P 5 0.03 for the AG
genotype at rs2551188) to 3.38 (95% CI 5 1.51–7.57; P 5 0.003 for
the TT genotype at rs2617266). An inverse association for disease
aggressiveness was found for men carrying the GG genotype at
rs1056836 as compared with the CC genotype (OR 5 0.45, 95%
CI 5 0.24–0.84, P 5 0.01) (Table V). In the Hispanic Caucasian
cases, marker rs2567206 showed a marginally signiﬁcant decrease
in the risk for disease aggressiveness (OR 5 0.44, P 5 0.04, 95%
CI 5 0.20–0.97; Table V).
Association of haplotypes with PCa risk or disease aggressiveness
Haplotype block structure was determined using the genotype data
from each race/ethnic group and deﬁned according to the default
settings proposed by Gabriel et al. (38). In the non-Hispanic Cauca-
sians, the pairwise D# values were .0.98 and all six SNPs were part
of one haplotype block. In the Hispanic Caucasians, high linkage
disequilibrium was found between the rs2567206-rs2551188-
rs2617266-rs10012 polymorphisms (D# values .0.98), and these four
SNPs are part of one haplotype block. A second haplotype block
encompassing rs1056836 and rs1800440 was present in this race/eth-
nic sample group. Therefore, there is no independent risk association
for the six SNPs in the Hispanic Caucasians and for the four strongly
linked SNPs in the non-Hispanic Caucasians.
Interestingly, when measuring the effect of PCa risk, a common
C-G-C-C-G-A haplotype (frequency of 22.9% in the study group)
for SNPs rs2567206-rs2551188-rs2617266-rs10012-rs1056836-rs
1800440 was found to decrease the risk for PCa in the Hispanic
Caucasian samples under the recessive model (OR 5 0.19, P 5 0.04,
95% CI 5 0.04–0.95; Table VI). No statistically signiﬁcant results
were found under the additive or dominant model in the Hispanic
Caucasian samples. Furthermore, we did not ﬁnd signiﬁcant results
in the non-Hispanic Caucasian samples when measuring the effect of
the risk of PCa (data not shown).
However, among non-Hispanic Caucasian men withmore aggressive
PCa, this C-G-C-C-G-A haplotype (frequency of 42.5% in the study
group)showedasigniﬁcantinverseassociation withdiseaseaggressive-
ness under the additive model (OR 5 0.64, P 5 0.008, 95% CI
5 0.47–0.89; Table VI). In this ethnic sample group, a second major
haplotype T-A-T-G-C-A (28.0%) for the six-SNP combination was
found to have an increased risk; this haplotype has the opposite alleles
at all, but the last, SNPs as compared with the protective haplotype
discussedaboveand wasfoundtosigniﬁcantlyincreasethe risk in cases
with a high grade of PCa under the additive model (OR 5 1.77,
P 5 0.002, 95% CI 5 1.24–2.53; Table VI). No signiﬁcant results
were found when measuring the effects of disease aggressiveness in
the cases of the Hispanic Caucasian samples (data not shown).
Discussion
The prostate is a hormone-responsive organ in which androgens are
believed to stimulate growth and secretory functions whereas
Table III. Allele frequencies for the more common allele by race/ethnicity and case-control status
SNP dbSNP rs
number
Common
allele
Non-Hispanic Caucasians Hispanic Caucasians NCBI reported
Europeans
Cases
(n 5 496)
Controls
(n 5 498)
P
a Cases
(n 5 153)
Controls
(n 5 240)
P
a
 1001C/T rs2567206 C 0.72 0.73 0.76 0.73 0.72 0.76 0.72
 263G/A rs2551188 G 0.72 0.73 0.60 0.71 0.69 0.54 0.72
 13C/T rs2617266 C 0.72 0.73 0.85 0.73 0.71 0.64 0.77
142C/G (R48G) rs10012 C 0.72 0.73 0.54 0.71 0.69 0.50 0.84
4326C/G(L432V) rs1056836 C 0.57 0.56 0.69 0.78 0.73 0.12 0.59
4390A/G(N453S) rs1800440 A 0.80 0.80 0.80 0.84 0.86 0.30 0.83
aAssumes Hardy–Weinberg equilibrium.
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SNP Genotype Hispanic Caucasians Non-Hispanic Caucasians
High grade
(n 5 59),
n (%)
Low grade
(n 5 61),
n (%)
OR
a 95% CI P Trend
P value
High grade
(n 5 149),
n (%)
Low grade
(n 5 215),
n (%)
OR
a 95% CI P Trend
P value
rs2567206 C/C 36 (61) 27 (44) 1.00 — 0.27 66 (44) 125 (58) 1.00 — 0.002
T/T 5 (8) 3 (5) 1.24 0.26–5.75 0.78 20 (13) 12 (6) 3.14 1.44–6.84 0.004
C/T 18 (31) 31 (51) 0.44 0.20–0.97 0.04 63 (43) 78 (36) 1.52 0.97–2.38 0.07
T/T þ C/T 0.52 0.25–1.08 0.08 1.74 1.14–2.66 0.01
rs2551188 G/G 33 (56) 27 (44) 1.00 — 0.50 64 (43) 125 (58) 1.00 — 0.002
A/A 5 (8) 3 (5) 1.35 0.29–6.29 0.70 19 (13) 12 (6) 3.08 1.40–6.75 0.005
A/G 21 (36) 31 (51) 0.57 0.26–1.22 0.14 66 (44) 78 (36) 1.64 1.05–2.57 0.03
A/A þ A/G 0.64 0.31–1.33 0.23 1.84 1.20–2.81 0.005
rs2617266 C/C 35 (59) 28 (46) 1.00 — 0.41 64 (43) 126 (59) 1.00 — 0.001
T/T 5 (8) 3 (5) 1.32 0.29–6.13 0.72 19 (13) 11 (5) 3.38 1.51–7.57 0.003
C/T 19 (33) 30 (49) 0.52 0.24–1.12 0.09 66 (44) 78 (36) 1.66 1.06–2.59 0.03
T/T þ C/T 0.59 0.28–1.24 0.16 1.87 1.22–2.86 0.004
rs10012 C/C 33 (56) 26 (43) 1.00 — 0.40 64 (43) 125 (58) 1.00 — 0.002
G/G 5 (8) 3 (5) 1.30 0.28–6.05 0.74 19 (13) 13 (6) 2.85 1.32–6.15 0.008
C/G 21 (36) 32 (52) 0.53 0.24–1.13 0.10 66 (44) 77 (36) 1.66 1.06–2.61 0.03
G/G þ C/G 0.59 0.29–1.24 0.16 1.84 1.20–2.81 0.005
rs1056836 C/C 35 (65) 34 (61) 1.00 — 0.57 58 (39) 60 (29) 1.00 — 0.01
G/G 1 (2) 2 (3) 0.47 0.04–5.68 0.55 21 (14) 49 (23) 0.45 0.24–0.84 0.01
C/G 18 (33) 20 (36) 0.87 0.39–1.94 0.73 69 (47) 102 (48) 0.71 0.44–1.14 0.16
G/G þ C/G 0.83 0.38–1.83 0.65 0.62 0.40–0.98 0.04
rs1800440 A/A 38 (66) 41 (71) 1.00 — 0.26 85 (63) 129 (66) 1.00 — 0.97
G/G 3 (5) 0 (0) ND ND ND 4 (3) 10 (5) 0.59 0.18–1.96 0.39
A/G 17 (29) 17 (29) 1.12 0.49–2.54 0.79 46 (34) 58 (29) 1.20 0.75–1.94 0.45
G/G þ A/G 1.31 0.59–2.92 0.51 1.11 0.70–1.76 0.65
High grade includes case with Gleason score  7, Low grade includes case with Gleason score ,7, ND, not determined.
aAdjusted for age. Signiﬁcant results are shown in bold.
Table IV. Association of CYP1B1 polymorphisms with PCa in Hispanic and non-Hispanic Caucasians
SNP Genotype Hispanic Caucasians Non-Hispanic Caucasians
Cases
(n 5 153),
n (%)
Controls
(n 5 240),
n (%)
OR
a 95% CI P Trend
P value
Cases
(n 5 496),
n (%)
Controls
(n 5 498),
n (%)
OR
a 95% CI P Trend
P value
rs2567206 C/C 80 (52) 126 (52) 1.00 — 0.97 266 (54) 275 (55) 1.00 — 0.74
T/T 10 (7) 21 (9) 0.85 0.37–1.96 0.70 44 (9) 46 (9) 1.00 0.64–1.57 0.99
C/T 63 (41) 93 (39) 1.12 0.72–1.74 0.61 186 (38) 177 (36) 1.08 0.83–1.42 0.54
T/T þ C/T 1.07 0.70–1.63 0.75 1.07 0.83–1.38 0.60
rs2551188 G/G 76 (50) 114 (48) 1.00 — 0.75 263 (53) 275 (56) 1.00 — 0.60
A/A 11 (7) 22 (9) 0.81 0.36–1.82 0.60 44 (9) 46 (9) 1.01 0.64–1.58 0.98
A/G 66 (43) 104 (43) 1.01 0.65–1.57 0.95 189 (38) 174 (35) 1.14 0.87–1.49 0.34
A/A þ A/G 0.98 0.64–1.49 0.92 1.11 0.86–1.43 0.41
rs2617266 C/C 80 (52) 123 (51) 1.00 — 0.92 265 (53) 270 (55) 1.00 — 0.82
T/T 10 (7) 21 (9) 0.80 0.35–1.86 0.61 43 (9) 46 (9) 0.97 0.61–1.53 0.89
C/T 63 (41) 95 (40) 1.10 0.70–1.70 0.69 188 (38) 176 (36) 1.09 0.83–1.42 0.54
T/T þ C/T 1.04 0.68–1.59 0.84 1.06 0.82–1.37 0.64
rs10012 C/C 76 (49) 113 (47) 1.00 — 0.74 262 (53) 275 (56) 1.00 — 0.53
G/G 11 (8) 22 (9) 0.80 0.36–1.82 0.60 45 (9) 46 (9) 1.04 0.66–1.63 0.87
C/G 66 (43) 105 (44) 1.01 0.65–1.57 0.96 189 (38) 175 (35) 1.14 0.87–1.49 0.35
G/G þ C/G 0.96 0.64–1.49 0.91 1.12 0.87–1.44 0.39
rs1056836 C/C 83 (58) 130 (55) 1.00 — 0.12 164 (33) 161 (33) 1.00 — 0.71
G/G 4 (3) 22 (9) 0.31 0.10–0.96 0.04 96 (20) 101 (20) 0.93 0.65–1.34 0.70
C/G 55 (39) 85 (36) 0.93 0.59–1.47 0.76 231 (47) 234 (47) 0.98 0.74–1.31 0.90
G/G þ C/G 0.82 0.53–1.26 0.36 0.97 0.74–1.27 0.81
rs1800440 A/A 104 (70) 170 (74) 1.00 — 0.36 299 (65) 309 (64) 1.00 — 0.80
G/G 4 (3) 3 (1) 1.70 0.35–824 0.51 19 (4) 22 (5) 0.90 0.47–1.70 0.74
A/G 41 (27) 57 (25) 1.19 0.73–1.93 0.48 142 (31) 148 (31) 0.99 0.75–1.31 0.94
G/G þ A/G 1.22 0.76–1.95 0.41 0.98 0.75–1.28 0.87
aAdjusted for age. Signiﬁcant results are shown in bold.
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1754estrogens act as growth inhibitors (39). Substantial evidence for a po-
tential role of CYP1B1 in PCa comes from the observations that
CYP1B1 protein is overexpressed in prostate carcinoma whereas no
CYP1B1 protein expression is detected in normal prostate tissue (17).
In addition, CYP1B1 has been implicated as an important gene upre-
gulated in PCa (40) and experiments with CYP1B1-knockout mice
show the critical role of this enzyme in 7,12-dimethylbenz(a)anthra-
cene-induced tumorigenesis (21). Furthermore, CYP1B1 is also
known to activate several carcinogens that are suspected to be in-
volved in PCa development (20) and expression of CYP1B1 was in-
creased in humanized mouse models after the removal of androgen
signaling via chemical or surgical castration (41).
In humans, CYP1B1 is genetically polymorphic and several com-
mon SNPs have been identiﬁed, four of which change the amino acid
sequence. A number of studies have investigated possible associations
of SNPs in the human CYP1B1 genewith the risk of PCa in Caucasian
(27,30,31) and in Japanese men (28,29). However, association analy-
sis of polymorphisms within CYP1B1 indicated that the signiﬁcant
ﬁndings are controversial, and/or several studies have failed to reveal
an association. Furthermore, no study to date has examined the role of
CYP1B1 variants in the Hispanic Caucasian men with PCa. To con-
ﬁrm previous ﬁndings in non-Hispanic Caucasians and to test the
hypothesis that CYP1B1 variants are associated with PCa risk in
Hispanic Caucasians, we performed a case–control genotype analysis
of six polymorphisms within CYP1B1 in 994 non-Hispanic Cauca-
sians and 393 Hispanic Caucasians.
No signiﬁcant differences were observed for allele frequencies be-
tween cases and controls of each race/ethnic group. In addition, the
allele distributions between cases with and without a family history of
PCa were not signiﬁcantly different excluding a possible bias in
genetic predisposition. In the Hispanic Caucasians, the GG genotype
at rs1056836 showed a marginally signiﬁcant decrease in the risk for
PCa when compared with the CC genotype. Moreover, a common
C-G-C-C-G-A haplotype (frequency of 22.9%) for the six consecutive
SNPs was found to be protective for PCa in the Hispanic Caucasian
samples. This is to our knowledge the ﬁrst report on the signiﬁcant
association of CYP1B1 genotypes and haplotypes with the risk to
develop PCa in Hispanic Caucasian men.
Among non-Hispanic Caucasian men with more aggressive PCa,
four of the six variants analyzed (rs2567206, rs2551188, rs2617266
and rs10012) were associated with the highest grade disease stage
whereas variant rs1056836 showed an inverse association with
disease aggressiveness. Furthermore, carrying the common C-G-C-
C-G-A haplotype for the six SNPs decreased the risk of PCa among
non-Hispanic Caucasian men with aggressive disease. In this sample
group, a second haplotype T-A-T-G-C-A (frequency of 28.0%) was
positively associated with the disease aggressiveness. This risk hap-
lotype shows the opposite allele at each SNP, exceptfor the rs1800440
variant, as compared with the haplotype that is found to be protective
in the Hispanic Caucasians and in the non-Hispanic Caucasians cases
with high-grade PCa. The reported signiﬁcance levels are nominal, in
particular in the Hispanic Caucasians, and were not adjusted for mul-
tiple comparisons. This inﬂates the probability of a false discovery
above the nominal P value, and tests of marginal signiﬁcance should
be interpreted cautiously given the number of hypotheses tested.
A Bonferroni correction applied across the SNPs is too conservative
here given that the SNPs are in strong linkage disequilibrium and are
not statistically independent. In order to lessen the bias towards pos-
itive ﬁndings, both positive and negative results are reported.
Our marginally signiﬁcant association results of rs1056836 with
PCa risk in the Hispanic Caucasians and signiﬁcant results in non-
HispanicCaucasianswithhighaggressivediseasestatussuggestapro-
tective effect of the G allele at rs1056836 rather than a risk effect. The
protective haplotype C-G-C-C-G-A that is signiﬁcantly associated
with PCa risk also showed the presence of the G allele at
rs1056836. This is in contrast with other studies that report on an in-
verse association between PCa and the rs1056827(T)-rs1056836(C)
haplotype (31) or a positive association with the rs1056836G/G ge-
notype alone (27). Moreover, our haplotype results are the opposite of
theﬁndingsofChangetal.(31)whoreportedonafrequentC-G-C-C-G
haplotype for rs2567206-rs2551188-rs2617266-rs10012-rs1056827
that increased the risk for PCa in Caucasian men. These discrepancies
might be seen because the allelic distribution of the CYP1B1 poly-
morphisms is different among different ethnicities, which could result
in the observed differences in the rate and development of PCa across
populations (42,43). Other possible explanations for between-study
variability could be that most of the reported association studies are
based on small sample sizes and might not give enough power to
detect true associations.
Functional studies indicate that certain combinations of alleles can
drastically alter the kinetic properties of CYP1B1 in the formation of
both the 2- and 4-hydroxylation of 17b-estradiol. Particularly, combi-
nations that contain the R48G, A119S and L432V amino acid sub-
stitutions had the highest Km and the lowest Vmax, indicating that
haplotype combinations of these SNPs might have important effects
on protein folding (44). However, the observed differences in catalytic
activity in some studies were relatively modest and/or variations
between laboratories exist (24–26,45,46). Furthermore, no differences
at the expression level of the protein were found with allelic changes
(47). Since no study has evaluated CYP1B1 estrogen metabolism in
human cells, there currently is no evidence on whether allelic
changes, either alone or in combination, can actually modulate the
catalytic activity of CYP1B1.
A direct role of CYP1B1 variants on the risk for PCa could be
supported by our ﬁndings suggesting that interindividual differences
in the activation of procarcinogens or in the metabolism of estrogen
Table VI. Association of common CYP1B1 haplotypes with PCa risk in Hispanic Caucasians or disease aggressiveness in non-Hispanic Caucasians
SNP combination Hispanic Caucasians Non-Hispanic Caucasians
PCa risk Disease aggressiveness
Frequency
(%)
No. of haplotypes OR
a 95% CI P
b Frequency
(%)
No. of haplotypes OR
a 95% CI P
c
Cases
(n 5 153)
Controls
(n 5 240)
High grade
(n 5 149)
Low grade
(n 5 215)
rs2567206-rs2551188-rs2617266-rs10012-rs1056836-rs1800440
C-G-C-C-G-A 22.9 2 14 0.19 0.04–0.95 0.04 42.5 81 138 0.64 0.47–0.89 0.008
T-A-T-G-C-A 27.3 10 19 0.79 0.35–1.79 0.57 28.0 77 81 1.77 1.24–2.53 0.002
C-G-C-C-C-G 14.8 4 3 1.82 0.35–9.46 0.47 19.2 50 64 1.14 0.77–1.71 0.51
C-G-C-C-C-A 31.8 16 24 1.04 0.52–2.08 0.91 9.3 22 35 0.79 0.47–1.34 0.38
High grade includes cases with Gleason  7, Low grade includes case with Gleason ,7. Only common haplotypes (.5%) are shown.
aOR is age adjusted.
bRecessive model.
cAdditive model. Signiﬁcant results are shown in bold.
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susceptibility of human cancers. However, CYP1B1 might contribute
in the risk for PCa in combination with other factors such as exposure
to carcinogens and carcinogenic metabolism, hormonal activation
causing genotoxicity and other genes that participate in CYP1B1-
mediatedpathways.Alternatively,theremaybeacausalvariantresiding
on or near the corresponding haplotype that affects the risk of PCa
development. Additional studies are needed to clarify the functional
signiﬁcance of our ﬁndings in the vulnerability/etiology of PCa.
Some of the limitations of this study are that race/ethnicity is self-
reported and the signiﬁcant differences seen in the genotype and
haplotype frequencies with PCa or disease aggressiveness could be
due to the population stratiﬁcation. However, we believe that possible
misclassiﬁcations are equally likely in cases and controls and there-
fore should not have a substantial impact on the outcome. Another
limitation is that bothincidence andprevalence cases were used inthis
study. The prevalent cases were recruited within the same time period
from the same metropolitan population and using the same means as
the incidence cases, such that both groups of cases corresponded as
much as possible. The power of this study is limited by the sample
size (994 non-Hispanic Caucasians and 393 Hispanic Caucasians), the
minor allele frequencies (MAF) (28–43%), the baseline incidence of
disease ( 6%) and the unknown OR of a genetic risk factor. Assum-
ing a Type I error of 0.05, an OR of 1.5 and a MAF of 30%, we
estimated the power of the study withthe method of Slager and Schaid
to be 99% and 73% in non-Hispanic Caucasians and Hispanic
Caucasians, respectively.
In conclusion, we conﬁrm the likely involvement of CYP1B1 in the
etiology of PCa and we further provide the ﬁrst evidence for an
association of the CYP1B1 gene with PCa in Hispanic Caucasian
men. The risk of CYP1B1 polymorphisms and PCa seems to be pop-
ulation-type dependent and further studies are warranted that address
the discrepant ﬁndings between different ethnicities.
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